Organic glues or fibrin glues from pooled plasma: Efficacy, safety and potential as scaffold delivery systems

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 1, 2012, Pages 124-140

  Tabélé, Clémence ^a   Montana, Marc ^b   Curti, Christophe ^b,c   Terme, Thierry ^b   Rathelot, Pascal ^b,c   Gensollen, Sophie ^a   Vanelle, Patrice ^b,c  

^a HÔPITAL DE LA CONCEPTION   (France)

^b AIX MARSEILLE UNIV   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; CEFALOTIN; CRYOSEAL; DOXORUBICIN; ETOPOSIDE; FIBRIN; FIBRIN GLUE; FIBRINOGEN; FIBRINOGEN PLUS THROMBIN; FLUOROURACIL; GENTAMICIN; LIDOCAINE; MITOMYCIN C; PLATELET RICH FIBRIN; QUIXIL; TACHOCOMB; TACHOCOMB H; TEGAFUR; TEICOPLANIN; THROMBIN; TISSUE SCAFFOLD; TRANEXAMIC ACID; UNCLASSIFIED DRUG; VANCOMYCIN; VASCULOTROPIN; VIVOSTAT;

ADVERSE OUTCOME; ANAPHYLACTIC SHOCK; ARTICLE; BLEEDING; CARDIOPULMONARY INSUFFICIENCY; CELL PROLIFERATION; CRYOPRECIPITATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; FEVER; GRAFT INFECTION; HUMAN; INTERMETHOD COMPARISON; MESENCHYMAL STEM CELL TRANSPLANTATION; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; PARTICLE SIZE; POSTOPERATIVE PAIN; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SKIN MANIFESTATION; STRESS INCONTINENCE; SURVIVAL RATE; TENSILE STRENGTH; TISSUE ENGINEERING;

EID: 84856768774     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/J39K5H     Document Type: Article

References (114)

1. Gerhard Dickneite, Hubert Metzner, Thomas Pfeifer, et al. A comparison of fibrin sealants in relation to their in vitro and in vivo properties. Thrombosis Research, 112:73-82, 2003.
2. Gerhard Dickneite, Hubert Metzner, Monika Kroez, et al. The Importance of Factor XIII as a Component of Fibrin Sealants. J Surg Res, 107:186-195, 2002.
3. Kaan Kavakli. Fibrin glue and clinical impact on haemophilia care. Haemophilia, 5(6):392-396, 1999.
4. Bernadette Tock, William N. Drohan, John R. Hess, et al. Haemophilia and advanced fibrin sealant technologies. Haemophilia, 4(4):449-455, 1998.
5. Paula HB. Bolton-Maggs. The management of factor XI deficiency. Haemophilia, 4(4):683-688, 1998.
6. Paula HB. Bolton-Maggs. Factor XI deficiency and its management. Haemophilia, 6(l):100-109, 2000.
7. Uri Martinowitz, David Varon, Michael Heim. The role of fibrin tissue adhesives in surgery of haemophilia patients. Haemophilia, 4(4):443-448, 1998.
8. Thierry Burnouf, Mirjana Radosevichm, Hadi A. Goubran. Local Hemostatic Blood Products: Fibrin Sealant and Platelet Gel. The World Federation of Hemophilia, 36:1-10, 2004.
9. Roger Tredree, Wolfram Beierlein, Isabelle Debrix, et al. Evaluating the differences between fibrin sealants: recommendations from an international advisory panel of hospital pharmacists. The European Journal of Hospital Pharmacy Science, 12(1):3-9, 2006.
10. Ronald W. Busuttil. A comparison of antifibrinolytic agents used in hemaostatic fibrin sealants. J Am Coll Surg, 197:1021-1028, 2003.
11. Peter Agger, Jesper Langhoff, Morten H. Smerup, et al. Comparison between TachoComb and TachoSil for surgical hemostasis in arterial bleeding: an animal experimental study. J Trauma, 68(4):838-842, 2010.
12. Ulrich Eberhard, Martin Broder, Günther Witzke. Stability of Beriplast® P fibrin sealant: Storage and reconstitution. Int J Pharm, 313:1-4, 2006.
13. Committee for Medicinal Products for Human Use. Guideline on the clinical investigation of plasma derived fibrin sealant/haemostatic products. London: EMEA, 6p, 2004.
14. Lilliana Bar, Osnat Malka, Elvira Naboichenko, Israel Nur. The binding of fibrin sealant to collagen is influenced by the method of purification and the cross-linked fibrinogen-fibronectin (heteronectin) content of the 'fibrinogen' component. Blood Coagul Fibrinolysis, 16:111-117, 2005.
15. Steven M Alston; Kenneth A Solen, Adam H Broderick, et al. New method to prepare autologous fibrin glue on demand. Translational Research, 149:187-195, 2007.
16. Richard R. Gammon, Nancy Avery, paul D. Mintz. Fibrin sealant: an evaluation of methods of production and the role of the blood bank. J Long Term Eff Med Implants, 8:103-116, 1998.
17. David H. Sierra. Fibrin sealant adhesive systems: a review of their chemistry, material properties and clinical applications. J Biomat Appl, 7:309-352, 1993.
18. Moon Suh, Choong Ik Cha. Biochemical aspects of autologous fibrin glue derived from ammonium sulfate precipitation. Laryngoscope, 103:193-196, 1993.
19. Thomas H. Barker, Gerald M Fuller, Martine M. Klinger, et al. Modification of fibrinogen with poly(ethylene glycol) and its effects on fibrin clot characteristics. J Biomed Mater Res, 56: 529-535.
20. Frederick H. Silver, Ming-Che Wang, George D. Pins. Preparation of Fibrin Glue: A Study of Chemical and Physical Methods. J Appl Biomater, 6:175-183, 1995.
21. Frederick H. Silver, Ming-Che Wang, GeorgeD. Pins. Preparation and use of fibrin glue in surgery. Biomaterials, 16:891-903, 1995.
22. Masafumi Kawamura, Makoto Sawafuji, Masazumi Watanabe, et al. Frequency of transmission of human parvovirus B19 infection by fibrin sealant used during thoracic surgery. Ann Thorac Surg, 73(4):1098-1100, 2002.
23. Masayuki Hino, Osamu Ishiko, Ken-ichi Honda, et al. Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgery. Br J Haematol, 108(1):194-195, 2000.
24. Mark R. Jackson, Martin J. MacPhee, William N. Drohan, et al. Fibrin sealant: current and potential clinical applications. Blood Coagul Fibrinolysis, 7(8):737-746, 1996.
25. Thomas L. Matthew, William D. Spotnitz, Irving L. Kron, et al. Four years' experience with fibrin sealant in thoracic and cardiovascular surgery. Ann Thorac Surg, 50(1):40-43, 1990.
26. Alexander P. Reiner, Fibrin glue increasingly popular for topical surgical hemostasis. Lab. Med, 30:189-193, 1999.
27. Udaya Kumar, David M. Albala. Fibrin glue applications in urology. Curr Urol Rep, 2(1):79-82, 2001.
28. Olivier Sterkers, Mohamed Badr el Dine, Maurice Bagot d'Arc, et al. Anastomosis of the facial nerve using fibrin glue, a propos of 60 cases. Rev Laryngol Otol Rhinol, 111(5):433-435, 1990.
29. Alexis Bozorg Grayeli, Isabelle Mosnier, Nicolas Julien et al. Long-term functional outcome in facial nerve graft by fibrin glue in the temporal bone and cerebellopontine angle. Eur Arch Otorhinolaryngol, 262(5):404-407, 2005.
30. Vera Van Velthoven, Georg Clarici, Ludwig M Auer. Fibrin tissue adhesive sealant for the prevention of CSF leakage following transsphenoidal microsurgery. Acta Neurochir, 109:26-29, 1991.
31. Kyu Chang Lee, Sang Keun Park, Kyu Sung Lee. Neurosurgical application of fibrin adhesive. Yonsei Med, 32:53-57, 1991.
32. Živko Gnjidic, Damir Tomac, Lucijan Negovetic, et al. Fibrin sealants in the management of cerebrospinal fistulae. Biomed Prog, 7:39-42, 1994.
33. Kintomo Takakura, Osami Kubo, Yasuhiko Tajika, et al. Efficacy and safety of the use of BI 91.021.3 (Beriplast) in cranial nerve surgery. Shinryo Shinyaku, 31:1808-1817, 1994.
34. Can Solakoǧlu, Mahir Mahiroǧullari, Selami Cakmak, et al. Fibrin sealant in the treatment of acute ruptures of the Achilles tendon: long-term results. Eklem Hastali{dotless}k Cerrahisi, 21(3): 124-129, 2010.
35. R. Justin Thoms, Scott E. Marwin. The role of fibrin sealants in orthopaedic surgery. J Am Acad Orthop Surg,17(12):727-736, 2009.
36. Myron Schwartz, Juan Madariaga, Ryutiao Hirose, et al. Comparison of a new fibrin sealant with standard topical haemostatic agents. Arch Surg, 139:1148-1154, 2004.
37. Abe Fingerhut, Nicolas Veyrie, Toufik Ata, et al. Use of sealants in pancreatic surgery: critical appraisal of the literature. Dig Surg, 26(1):7-14, 2009.
38. Héctor D. González, Joan Figueras. Topical hemostatic devices in surgery: between science and marketing. Cir Esp, 85(1):23-28, 2009.
39. Takahiro Kinoshita, Shinichiro Miyoshi, Takaomi Suzuma T, et al. Intrapleural administration of a large amount of diluted fibrin glue for intractable pneumothorax. A clinical study based on 57 cases: including 2 unsuccessful cases. Jpn J Thorac Cardiovasc Surg, 51(2):41-47, 2003.
40. Shikha Sarkar, Naveed Hussain, Victor Herson. Fibrin glue for persistent pneumothorax in neonates. J Perinatol, 23(1):82-84, 2003.
41. Masatoshi Kurihara, Hideyuki Kataoka, Aki Ishikawa, et al. Latest treatments for spontaneous pneumothorax. Gen Thorac Cardiovasc Surg, 58(3):113-119, 2010.
42. José Alcorta, Richard Audry, Cécile Cousté, et al. Collage dans le médical: Zoom sur les applications « In Vivo ». Innovalis Collage Actualités, 81:1-8, 2010.
43. Anne Y. Abaut. 17èmes journées nationales sur les dispositifs médicaux. Revue des substances hémostatiques chirurgicales, 2007 oct, Nantes, France.
44. Nur Israel, Yacov Lyahovetsky, Liliana Bar, et al. Commercial fibrin sealants are not equivalent in a rabbit liver-resection model which quantitatively evaluates hemostasis and formation of adhesions. Eur Surg Res, 37(3):159-165, 2005.
45. GJ Wang, David S. Hungerford, Carlton G. Savory, et al. Use of fibrin sealant to reduce bloody drainage and hemoglobin loss after total knee arthroplasty: a brief note on a randomized prospective trial. J Bone Joint Surg Am, 83:1503-1505, 2001.
46. Martin P Sintler, Asif Mahmood, Simon RG Smith, et al. Quixil surgical sealant in carotid endarterectomy with ePTFE patch reconstruction. World J Surg, 29(10): 1259-1262, 2005.
47. Anthony J. Rousou, Sidney Levitsky, Lorenzo Gonzalez-Lavin, et al. Randomized clinical trial of fibrin sealant in patients undergoing resternotomy or reoperation after cardiac operations. A multicenter study. J Thorac Cardiovasc Surg, 97:194-203, 1989.
48. Stefano Olmi, Alberto Scaini, Luigi Erba, et al. E. Use of fibrin glue (Tissucol) as a hemostatic in laparoscopic conservative treatment of spleen trauma. Surg Endosc, 21(11):2051-2054, 2007.
49. Francesco La Torre, Giuseppe Pascarella, Alessia P. Nicolai, et al. Use of human fibrin glue (Tissucol) in the treatment of recurrent fistulas. G Chir, 16(5):257-258, 1995.
50. Christopher J. Dunn, Karen L. Goa. Fibrin sealant: a review of its use in surgery and endoscopy. Drugs, 58: 863-886, 1999.
51. Andreas Rickenbacher, Stefan Breitenstein, Mickael Lesurtel, et al. Efficacy of TachoSil a fibrin-based haemostat in different fields of surgery--a systematic review. Expert Opin Biol Ther, 9(7):897-907, 2009.
52. William L. Hickerson, Israel Nur, Roberto Meidler. A comparison of the mechanical, kinetic, and biochemical properties of fibrin clots formed with two different fibrin sealants. Blood Coagul Fibrinolysis, 22(1):19-23, 2011.
53. Roderick T., Chalmers Darling Iii, et al. Randomized clinical trial of tranexamic acidfree fibrin sealant during vascular surgical procedures. Br J Surg, 97(12):1784-1789, 2010.
54. Shepherd G. Pryor, Jonathan Sykes, Travis T. Tollefson. Efficacy of fibrin sealant (human) (Evicel) in rhinoplasty: a prospective, randomized, single-blind trial of the use of fibrin sealant in lateral osteotomy. Arch Facial Plast Surg, 10(5):339-344, 2008.
55. Naoki Minato, Yuji Katayama, Junji Yunoki. Hemostatic Effectiveness of a New Application Method for Fibrin Glue "The Rub-And-Spray Method" in Emergency Aortic Surgery for Acute Aortic Dissection. Ann Thorac Cardiovasc Surg, 15(4):265-271, 2009.
56. Louise Z. Wang, Jed Gorlin, Sarah E. Michaud, et al. Purification of Salmon Clotting Factors and Their Use as Tissue Sealants. Thromb Res, 100:537-548, 2000.
57. Abha Sahni, Charles W. Francis. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation, Blood, 96(12):3772-3778, 2000.
58. Isabelle Catelas, Joseph F Dwyer, Sam Helgerson. Controlled release of bioactive transforming growth factor beta-1 from fibrin gels in vitro, Tissue Eng Part C Methods. 14(2):119-128, 2008.
59. Abha Sahni, Tatjana Odrljin, Charles W. Francis. Binding of basic fibroblast growth factor to fibrinogen and fibrin, J Biol Chem, 273:7554-7559, 1998.
60. Phil G. Campbell, Susan K. Durham, James D. Hayes, et al. Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin, J Biol Chem, 274: 30215-30221, 1999.
61. Catalina Wong, Elisabeth Inman, Reiner Spaethe, et al. Fibrin-based biomaterials to deliver human growth factors, Thromb Haemost, 89:573-582, 2003.
62. Jan C. Becker, Wolfram Domschke, Thorsten Pohle. Biological in vitro effects of fibrin glue: fibroblast proliferation, expression and binding of growth factors, Scand J Gastroenterol, 39:927-932, 2004.
63. Shao-ping Nie, Wang Xiao, Qiao Shi-bin, et al. Improved myocardial perfusion and cardiac function by controlled-release basic fibroblast growth factor using fibrin glue in a canine infarct model. Journal of Zhejiang University-Science B (Biomedecine & Biotechnologie), 11(12): 895-904, 2010.
64. Amgad M. Haleem, Abdel A. Singergy, Dina Sabry, et al. The Clinical Use of Human Culture-Expanded Autologous Bone Marrow Mesenchymal Stem Cells Transplanted on Platelet-Rich Fibrin Glue in the Treatment of Articular Cartilage Defects: A Pilot Study and Preliminary Results. Cartilage, 1(4):253-261, 2010.
65. Boaz Mizrahi, Christopher Weldon and Daniel S. Kohane. Tissue Adhesives as Active Implants. Stud Mechanobiol Tissue Eng Biomater, 8:39-56, 2011.
66. Xiao Zhibo, Zhang Miaobo. Effect of Sustained-Release Lidocaine on Reduction of Pain after Subpectoral Breast Augmentation. Aesthetic Surg J, 29:32-34, 2009.
67. Shin-ichiro Kitajiri, Keisaku Tabuchi, Harukazu Hiraumi, et al. Relief of post-tonsillectomy pain by release of lidocaine from fibrin glue. Laryngoscope, 111(4 Pt 1):642-644, 2001.
68. Katsuhiro Fujimoto, Keiko Yamamura, Takashi Osada, et al. Subcutaneous tissue distribution of vancomycin from a fibrin glue/Dacron graft carrier. Inc. J Biomed Mater Res, 36: 564-567, 1997.
69. Shinji Miyamoto, Tetsuo Hadama, Hideyuki Tanaka, et al. MRSA Aortic Valve Endocarditis Treated by Pericardium-lined Dacron Patch and Vancomycin-Containing Fibrin Glue. Case report. Ann Thorac Cardiovasc Surg, 10:252-254, 2004.
70. Piero Marone, Vincenza Monzillo, Çatia Segù, et al. Antibiotic-impregnated fibrin glue in ocular surgery: in vitro antibacterial activity. Ophthalmologica, 213(1):12-15, 1999.
71. Hidenori Kitazawa, Hitoshi Sato, Isao Adachi, et al. Microdialysis assessment of fibrin glue containing sodium alginate for local delivery of doxorubicin in tumor-bearing rats. Biological and Pharmaceutical Bulletin 20(3): 278-281, 1997.
72. Hisahiro Yoshida, Yasuhiro Yamaoka, Mizuya Shinoyama, et al. Novel Drug Delivery System Using Autologous Fibrin Glue-Release Properties of Anti-cancer Drugs-Biological and Pharmaceutical Bulletin 23 (3): 371-374, 2000.
73. Oscar K Lee. Fibrin Glue as a Vehicle for Mesenchymal Stem Cell Delivery in Bone Regeneration. Journal of the Chinese Medical Association, 71(2):59-61, 2008.
74. Frédéric Braccini, Ehrenfest DM. Dohan. De l'intérêt du Platelet Rich Fibrin (PRF) de Choukroun au cours de la lipostructure faciale esthétique de Coleman: résultats préliminaires. Rev Laryngol Otol Rhinol, 128(4):255-260, 2007.
75. Charles Volpei, Henri Sabatier. Facial aesthetic lipostructure. Rev Laryngol Otol, 127(1-2):51-56, 2006.
76. Y Xu, YF Song, ZX Lin. Transplantation of muscle-derived stem cells plus biodegradable fibrin glue restores the urethral sphincter in a pudendal nerve-transected rat model. Braz J Med Biol Res, 43(11):1076-1083, 2010.
77. Stephen Zoegall. Society for the Advancement of Blood Management study shows advantages of fibrin sealant over manual compression. J Vasc Nurs, 26(1):5, 2008.
78. Mario Testini, Germana Lissidini, Elisabetta Poli, et al. A single-surgeon randomized trial comparing sutures, N-butyl-2-cyanoacrylate and human fibrin glue for mesh fixation during primary inguinal hernia repair. Can J Plast Surg, 53(3):154-160, 2010.
79. Giampiero Campanelli, Diego Pettinari, Marta Cavalli. A modified Lichtenstein hernia repair using fibrin glue. Journal of Minimal Access Surgery, 2(3):129-133, 2006.
80. Pramod T. Shinde. Fibrin Sealant versus Use of Tackers for Fixation of Mesh in Laparoscopic Inguinal Hernia Repair. World Journal of Laparoscopic Surgery,2(1):42-48, 2009.
81. Paulo Negro, Francesco Basile, Antonio Brescia, et al. Open tension-free Lichtenstein repair of inguinal hernia: use of fibrin glue versus sutures for mesh fixation. Hernia, 15:7-14, 2011.
82. Grozdana Bilic, Carrie Brubaker, Phillip B Messersmith, et al. Injectible candidate sealants for fetal membrane repair: Bonding and toxicity in vitro. Am J Obstet Gynecol, 202(1): 851-859, 2010.
83. Roland Devlieger, Lynnae K. Millar, Gillian Bryant-Greenwood, et al. Fetal membrane healing after spontaneous and iatrogenic membrane rupture: A review of current evidence. Am J Obstet Gynecol, 195(6):1512-1520, 2006.
84. François Pigot, Laurent Siproudhis. Fistules anales et colle biologique. Le Courrier de coloproctologie (IV), 4:117-119, 2003.
85. Daniel C. Damin, Mário A. Rosito, Paulo C. Contu. Fibrin glue in the management of complex anal fistula. Arq Gastroenterol, 46(4):300-304, 2009.
86. Jean Charles Grimaud, Nicolas Munoz-Bongrand, Laurent Siproudhis, et al. Gastroenterology, 138(7):2275-2281, 2010.
87. Saliha Karagöz Avci, Serdar Yüceyar, Erman Aytaç. Comparison of classical surgery and sutureless repair with DuraSeal or fibrin glue for duodenal perforation in rats. Ulus Travma Acil Cerrahi Derg, 17(1): 9-13, 2011.
88. Bijan S. Kheirabadi, Rebecca Pearson, David Tuthill, et al. Comparative study of the hemostatic efficacy of a new human fibrin sealant: is an antifibrinolytic agent necessary? J Trauma, 52(6):1107-1115, 2002.
89. Micheline Berruyer, Jean Amiral, Patrick French, et al. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors. J Thorac Cardiovasc Surg, 105(5):892-897, 1993.
90. Hans Bänninger, Theres Hardegger, Andreas Tobler, et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol, 85(3):528-532 1993.
91. Sara J. Israels. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin. Am J Pediatr Hematol Oncol, 16(3):249-254, 1994.
92. Christophe Leroy-Matheron, Ariane Mallat, Christophe Duvoux, et al. Inhibitor against coagulation factor V after liver transplantation. Transplantation, 68(7):1054-1056, 1999.
93. James L. Zehnder, Lawrence L. Leung. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood, 76(10):2011-2016, 1990.
94. Wolfram Beierlein, Albertus M. Scheule, Wulf Dietrich, et al. Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. Ann Thorac Surg, 79:741-748, 2005.
95. Anne-Marie Oswald, Luc-Marie Joly, Charles Gury, et al. Fatal intraoperative anaphylaxis related to aprotinin after local application of fibrin glue. Anesthesiology, 99: 762-763, 2003.
96. Albertus M. Scheule, Wolfram Beierlein, Hans P. Wendel, et al. Aprotinin in fibrin tissue adhesives induces specific antibody response and increases antibody response of high-dose intravenous application. J Thorac Cardiovasc Surg, 118:348-358, 1999.
97. Yuzaburo Kanazawa, Shun Sato, Naotaka Iwamoto. Allergic reaction Following Arachnoid Plasty With a Fibrin Sealant. Neurol Med Chir, 50:608-610, 2010.
98. Walter Furst, Asmita Banerjee, Heinz Redl. Comparison of structure, strength and cytocompatibility of a fibrin matrix upplemented either with tranexamic acid or aprotinin. J Biomed Mater Res B Appl Biomater, 82(1):109-114, 2007.
99. Catherine M. Pipan, William P. Glasheen, Thomas L. Matthew, et al. Effects of antifibrinolytic agents on the life span of fibrin sealant. Abstract. J Surg Res, 53(4):402-407, 1992.
100. Joost de Vries, Tomas Menovsky, Sander van Gulik, et al. Histological Effects of Fibrin Glue on Nervous Tissue. Surg Neurol, 57:415-422, 2002.
101. Christoph Buchta, Hans Christian Hedrich, Maria Macher, et al. Biochemical characterization of autologous fibrin sealants produced by CryoSeal and Vivostat in comparison to the homologous fibrin sealant product Tissucol/Tisseel. Biomaterials, 26:6233-6241, 2005.
102. Jose L. Velada, Derek A. Hollingsbee, Alan R. Menzies, et al. Reproductibility of the mechanichal properties of Vivostat® system patient-derived fibrin sealant. Biomaterials, 23:2249-2254, 2002.
103. Steven M. Alston, Kenneth A. Solen, Sivaprasad Sukavaneshvar, et al. In Vivo Efficacy of a New Autologous Fibrin Sealant. J Surg Res, 146:143-148, 2008.
104. Christoph Buchta, Markus Dettke, Philipp T Funovics, et al. Impact of manufacturing, irradiation and filtration steps to bacterial contamination of autologous fibrin sealant. Biologicals, 32:162-169, 2004.
105. Mauro Valbonesi. Fibrin glues of human origin. Best Pract Res Clin Haematol, 19(1):191-203, 2006.
106. Marco Gipponi, Giuliano Reboa, Tommaso Testa, et al. Tension-free primary closure with autologous platelet gel versus Vivostat- for the definitive treatment of chronic sacrococcygeal pilonidal disease. In Vivo, 24(4):583-589, 2010.
107. Elizabeth Belcher, Michael Dusmet, Simon Jordan, et al. A prospective, randomized trial comparing BioGlue and Vivostat for the control of alveolar air leak. J Thorac Cardiovasc Surg, 140(1):32-38, 2010.
108. Alessandra Picardi, Alessandro Lanti, Laura Cudillo, et al. Platelet gel for treatment of mucocutaneous lesions related to graft-versushost disease after allogeneic hematopoietic stem cell transplant. Transfusion, 50(2):501-506, 2010.
109. Michael R. Lassen, Søren Solgaard, Anne G. Kjersgaard, et al. A pilot study of the effects of Vivostat patient-derived fibrin sealant in reducing blood loss in primary hip arthroplasty. Clin Appl Thromb Hemost, 12(3):352-357, 2006.
110. Ali Belboul, Leif Dernevik, Obaid Aljassim et al. The effect of autologous fibrin sealant (Vivostat) on morbidity after pulmonary lobectomy: a prospective randomised, blinded study. Eur J Cardiothorac Surg, 26(6):1187-1191, 2004.
111. John B. Hanks, Henrik K. Kjaergard, Derek A. Hollingsbee. A comparison of the haemostatic effect of Vivostat patient-derived fibrin sealant with oxidised cellulose (Surgicel) in multiple surgical procedures. Eur Surg Res, 35(5):439-444, 2003.
112. Henrik K. Kjaergard, Horace R. Trumbull. Bleeding from the sternal marrow can be stopped using vivostat patient-derived fibrin sealant. Ann Thorac Surg. 69(4):1173-1175, 2000.
113. Henrik K. Kjaergard, Horace R. Trumbull. Vivostat system autologous fibrin sealant: preliminary study in elective coronary bypass grafting. Ann Thorac Surg, 66(2):482-486, 1998.
114. Claus Moser, Isabelle Opitz, Wei Zhai, et al. Autologous fibrin sealant reduces the incidence of prolonged air leak and duration of chest tube drainage after lung volume reduction surgery: A prospective randomized blinded study. J Thorac Cardiovasc Surg, 136 (4):843-849, 2008.